WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership
BEIJING and SHANGHAI, May 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Tsinghua University Innovation Center for Immune Therapy (IC...
WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore
SINGAPORE and SHANGHAI, May 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to investS$80 million (equivalent to a...
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis' Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics' expertise in developing complex biologic
molecules for production of xB3-001 to support analytical development,
formulation and IND-enabling in vivo studies
SHANGHAI and VANCOUVER, British Columbia, May 21, 2018 /PRNewswire/ -- WuXi
Biologics
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang
BEIJING, China, May 16, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development,...
WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland
DUNDALK, Ireland and SHANGHAI, April 30, 2018 /PRNewswire/ -- An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over fiv...
WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine
SHANGHAI, April 16, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had won CMO Leadership Award for Reliability at the 2...
WuXi Biologics to Install Industry's Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility
WUXI, China and BETHLEHEM, Pa., March 20, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has selected 4,000 liter (L) Cu...
WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million
Revenue up 63.7% to a Record High of RMB1,618.8 Million Adjusted Net Profit up 85.1% to RMB408.1 Million Gross Profit Margin, Net Profit Margin and Adjusted Net Profit Margin All Increased Significantly Eight Late-Phase (Phase III) Projects Versus Three as of December 31, 2016 Total Integrated...
WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership
SHANGHAI, March 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Adagene Inc., an emerging biotech company discovering and developing in...
WuXi Biologics Receives Asia's CMO of 2017 from BioPharma Industry Awards
SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it had receivedAsia's CMO of 2017 at the 8th Annual BioPh...
WuXi Biologics Announces Positive Profit Alert
SHANGHAI, March 5, 2018 /PRNewswire/ -- WuXi Biologics (Stock Code: 2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, announced that based on the preliminary assessment of the unaud...
WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311
SHANGHAI, Feb. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner MabSpace Biosciences for FDA Investigational New ...
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development
SHANGHAI, Feb. 8, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today congratulated its partner Tychan for dosing the first patient with a fir...
WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC
SHANGHAI, Jan. 30, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner BioAtla® LLC for U.S. Investigational New Drug appli...
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
WUXI, China and HOUSTON, Jan. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Aravive Biologics, Inc., today announced plans to expand...
WuXi Biologics Announces Formation of Scientific Advisory Board
SHANGHAI, Jan. 24, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment of five internationally recognized scientis...
WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer
WUXI, China, Jan. 14, 2018 /PRNewswire/ -- WuXi Biologics (WuXi Bio, 02269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce that Dr. Chiang Syin has joined WuXi ...
WuXi Biologics and Phanes Sign MOU and Announce Strategic Development and Manufacturing Partnership
SHANGHAI and SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Phanes Therapeutics, Inc. (Phanes), an innovative drug di...
WuXi Biologics Initiated cGMP Manufacturing in the World's Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors
WUXI, China, Dec. 6, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its cGMP biologics manufacturing facility in Wuxi c...
WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory
SHANGHAI, Nov. 2, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its partner Pall Corporation, the global leader of advanced filtration, ...
